U.S. Senate to Continue Consideration of 21st Century Cures Wednesday

Dec. 7, 2016
By a vote of 85 to 13, the U.S. Senate on Monday invoked cloture for H.R. 34, the 21st Century Cures Act. The Senate resumed post-cloture consideration of the bill on Tuesday and and will now resume on Wednesday, with a vote likely at 2 pm.

By a vote of 85 to 13, the U.S. Senate on Monday invoked cloture for H.R. 34, the 21st Century Cures Act. The Senate resumed post-cloture consideration of the bill on Tuesday and and will now resume on Wednesday, with a vote likely at 2 pm.

U.S. House of Representative Energy and Commerce Committee Chairman Fred Upton (R-MI) and Rep. Diana DeGette (D-CO), sponsors of the 21st Century Cures Act, issued the following statement following the Senate’s cloture vote: "With today’s resounding vote, we’re excited the decks have been cleared for 21st Century Cures,” Upton and DeGette said. “This effort represents the very best of Congress, coming together and working toward a greater cause, a cause for hope. We were particularly delighted to share in the moment with Vice President Biden, NIH’s Dr. Collins, and Ellen Sigal. This is a big deal. After three years on the #Path2Cures, there’s a light at the end of the tunnel, and it’s called the White House. We can say with certainty - #CuresNow, it’s going to happen.”

Sponsored Recommendations

Ask the Expert: Is Your Patients' Understanding Putting You at Risk?

Effective health literacy in healthcare is essential for ensuring informed consent, reducing medical malpractice risks, and enhancing patient-provider communication. Unfortunately...

Beyond the Silos: Transforming Coordinated Care Across Healthcare Systems

Coordinated healthcare is vital to delivering a high-quality patient experience, yet it has been difficult to systematize across all healthcare settings. Although it has largely...

The Healthcare Provider's Guide to Accelerating Clinician Onboarding

Improve clinician satisfaction and productivity to enhance patient care

ASK THE EXPERT: ServiceNow’s Erin Smithouser on what C-suite healthcare executives need to know about artificial intelligence

Generative artificial intelligence, also known as GenAI, learns from vast amounts of existing data and large language models to help healthcare organizations improve hospital ...

According to an Oct. 10 press release, a report by the World Health Organization (WHO) finds that vaccines against 24 pathogens could reduce the number of antibiotics needed by 22% or 2.5 billion defined daily doses globally every year, supporting worldwide efforts to address antimicrobial resistance (AMR). While some of these vaccines are already available but underused, others would need to be developed and brought to the market as soon as possible. AMR occurs when bacteria, viruses, fungi, and parasites no longer respond to antimicrobial medicines, making people sicker and increasing the risk of illness, death and the spread of infections that are difficult to treat. AMR is driven largely by the misuse and overuse of antimicrobials, yet, at the same time, many people around the world do not have access to essential antimicrobials. Each year, nearly 5 million deaths are associated with AMR globally. Vaccines are an essential part of the response to reduce AMR as they prevent infections, reduce the use and overuse of antimicrobials, and slow the emergence and spread of drug-resistant pathogens. The new report expands on a WHO study published in BMJ Global Health last year. It estimates that vaccines already in use against pneumococcus pneumonia, Haemophilus influenzae type B (Hib, a bacteria causing pneumonia and meningitis) and typhoid could avert up to 106 000 of the deaths associated with AMR each year. An additional 543 000 deaths associated with AMR could be averted annually when new vaccines for tuberculosis (TB) and Klebsiella pneumoniae, are developed and rolled out globally. While new TB vaccines are in clinical trials, one against Klebsiella pneumoniae is in early stage of development.
dreamstime_xxl_210174616_1